# GLP-1 Drugs in Idiopathic Intracranial Hypertension: A Four-Study Meta-Analysis

What an exenatide trial and a four-study review found about GLP-1 drugs, intracranial pressure and symptoms in idiopathic intracranial hypertension.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/intracranial-pressure-and-a-thin-evidence-base
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 Drugs in Idiopathic Intracranial Hypertension: A Four-Study Meta-Analysis

A small exenatide trial measured lower pressure. A four-study review found associations with less papilledema, with limited evidence from randomized trials.

Editorial profile: [Neil Sanders](https://buythisglp.com/authors/neil-sanders)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20263 min readUpdated November 2026

Relative risk against standard care · 1.0 · papilledema · visual disturbance · headache · Estimates come from different study subsets.

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   Idiopathic intracranial hypertension raises pressure around the brain and can threaten sight.
-   A small randomized trial measured lower pressure with exenatide than with placebo.
-   Pooled estimates for symptoms and signs rely mostly on nonrandomized data.

Because weight is relevant to idiopathic intracranial hypertension, [weight loss with GLP-1 drugs](https://buythisglp.com/research/how-much-weight-will-i-lose-on-a-glp1) offers one reason to study these medicines. Researchers have also tested whether a drug can lower pressure directly.

## What the pressure trial measured

A small trial randomized 15 women with active disease to exenatide or placebo [\[2\]](https://buythisglp.com/research/intracranial-pressure-and-a-thin-evidence-base#ref-2). The researchers measured pressure directly. It was lower with exenatide at 2.5 hours and 24 hours. The 12-week result met the trial's prespecified threshold of p<0.10, with p=0.058.

The study was too small to establish long-term benefit or explain how pressure changed. An uncertain result for body mass index cannot establish whether weight played a role.

## What the pooled studies found

The 2025 review covered 1,550 patients across a trial, a nonrandomized study and two registry studies [\[1\]](https://buythisglp.com/research/intracranial-pressure-and-a-thin-evidence-base#ref-1). Different subsets contributed to different outcomes. The estimated relative risk for papilledema was 0.25 (95% CI 0.15 to 0.43). Papilledema means swelling of the optic disc.

The headache risk estimate was imprecise. It ranged from a substantial reduction to a slight increase. The studies reported digestive symptoms, with limited evidence to estimate uncommon or long-term harms.

Suspected intracranial hypertension needs clinical assessment. Treatment decisions depend on symptoms, pressure and the risk to vision.

## Frequently asked

Can GLP-1 drugs lower intracranial pressure?

A small randomized trial found lower pressure with exenatide than with placebo. Larger studies would help establish whether the effect lasts.

Did the review establish that GLP-1 drugs protect vision?

The review reported associations with less papilledema and fewer visual problems. Most of the evidence came from nonrandomized studies.

## Sources

1.  \[1\] Stefanou MI, et al. (2025). Efficacy and Safety of GLP-1 and Dual GIP/GLP-1 Receptor Agonists in Idiopathic Intracranial Hypertension: A Systematic Review and Meta-Analysis European Journal of Neurology. [PMID 40937960](https://onlinelibrary.wiley.com/doi/10.1111/ene.70358)
2.  \[2\] Mitchell JL, Lyons HS, Walker JK, et al. (2023). The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial Brain. [PMID 36907221](https://academic.oup.com/brain/article/146/5/1821/7065075)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
